Coniferyl Alcohol label

Coniferyl Alcohol

Coniferyl Alcohol Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

If pregnant or breast-feeding, ask a health care professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Do not use if tamper evident seal is broken or missing.

Store in cool, dry place.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

For temporary relief of chest congestion with constriction, headaches, sinus congestion, and rhinitis with discharge.

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Coniferyl Alcohol Manufacturers

  • Bioactive Nutritional, Inc.
    Coniferyl Alcohol | Bioactive Nutritional, Inc.
    No Recall

    Coniferyl Alcohol | Bioactive Nutritional, Inc.

    Coniferyl Alcohol | Bioactive Nutritional, Inc.

    10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.

  • Coniferyl Alcohol | Apotheca Company
    No Recall

    Coniferyl Alcohol | Apotheca Company

    Coniferyl Alcohol | Apotheca Company

    DIRECTIONS:  1-10 drops under the tongue, 3 times a day or as directed by a health professional.  Consult a physician for use in children under 12 years of age.


  • Deseret Biologicals, Inc.
    Coniferyl Alcohol | Oceanside Pharmaceuticals
    No Recall

    Coniferyl Alcohol | Oceanside Pharmaceuticals

    Coniferyl Alcohol | Oceanside Pharmaceuticals

    The usual dosage of pentoxifylline extended-release tablet form is one tablet (400 mg) three times a day with meals.

    While the effect of pentoxifylline may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.

    Digestive and central nervous system side effects are dose related. If patients develop these effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of pentoxifylline extended-release tablet should be discontinued.

    In patients with severe renal impairment (creatinine clearance below 30 mL/min) reduce dose to 400 mg once a day. Dosing information cannot be provided for patients with hepatic impairment.